Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting

Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting

Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery followed by radioactive iodide therapy. However, a small subset of patients shows recurrence due to a loss of iodide transport, a phenotype frequently associated with BRAF V600E mutations. In theory, this should...

Full description

Bibliographic Details
Main Authors: Riet Hilhorst, Adrienne van den Berg, Piet Boender, Tom van Wezel, Tim Kievits, Rik de Wijn, Rob Ruijtenbeek, Willem E. Corver, Hans Morreau
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
thyroid
<i>BRAF</i> mutation
dabrafenib
kinase activity profiling
peptide microarray
Online Access:https://www.mdpi.com/2072-6694/15/18/4477

Internet

https://www.mdpi.com/2072-6694/15/18/4477

Similar Items